Biogen (BIIB) Wānana Kūʻai Kūʻai
Kaʻu kumukūʻai hope$227.93Hoʻohou ʻia 25 Kep. 2026 19:59 UTC
Hoʻololi+0.69%
Hōʻoia AI: BIIB
Hoʻopuka ka AI i kahi kumukūʻai pahuhopu no ka lā kālepa aʻe, ka hopena pule a me ka hopena mahina. Hoʻomākaukau ʻia ka hoʻololi mai ka kumukūʻai hou loa. He helnau kūlana helu wale nō kēia, ʻaʻole he ʻōlelo aʻoaʻo hoʻopukapuka.
Kumukūʻai ma luna o nā mahina 6 i hala
Hōʻike ʻo Premium i nā pahuhopu kumukūʻai o ka AI no 1 lā, 1 pule a me 1 mahina no kēia a me nā stock ʻē aʻe.
Wehe iā Premium🔒 Moʻolelo hōʻike wānana
The forecast track record — every past forecast next to the actual close — is part of Premium.
Wehe iā PremiumE pili ana i kēia Hui
Biogen Inc. develops, manufactures, and commercializes therapies with a focus on neurology, oncology, and immunology. The company’s products are designed to treat conditions such as multiple sclerosis, non-Hodgkin lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis.
